Shandong Lukang Pharmaceutical (600789) Fundamentals 2026 — P/E 42.4x, Revenue Analysis | SniperIQ
Shandong Lukang Pharmaceutical (600789) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.5B, trading at ¥7.28 on the SHH. This SniperIQ fundamentals page covers Shandong Lukang Pharmaceutical's valuation (P/E 42.4x, P/B 1.5x), profitability (net margin 2.7%), revenue (¥5.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Lukang Pharmaceutical's market cap?
Shandong Lukang Pharmaceutical (600789) has a market capitalization of approximately ¥6.5B, trading at ¥7.28 on the SHH. Market cap moves with the live share price.
What is Shandong Lukang Pharmaceutical's P/E ratio?
Shandong Lukang Pharmaceutical's trailing twelve-month P/E ratio is 42.4x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shandong Lukang Pharmaceutical?
Shandong Lukang Pharmaceutical runs a net profit margin of 2.7%, a gross margin of 21.1%, and an operating margin of 3.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Lukang Pharmaceutical generate?
Shandong Lukang Pharmaceutical reported revenue of ¥5.8B for fiscal year 2025, with net income of ¥112M and earnings per share (EPS) of 0.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Lukang Pharmaceutical pay a dividend?
Shandong Lukang Pharmaceutical offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Lukang Pharmaceutical financially healthy?
Shandong Lukang Pharmaceutical carries a debt-to-equity ratio of 0.58x and a current ratio of 1.53x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Lukang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Lukang Pharmaceutical (600789) the key facts are: market cap ¥6.5B, P/E 42.4x, revenue ¥5.8B, 52-week range 6.48-11.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shandong Lukang Pharmaceutical's full fundamentals live
Get Shandong Lukang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.